Quince Therapeutics, Inc. (QNCX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
QNCX Revenue Growth
QNCX Revenue Analysis (2017–2025)
As of May 8, 2026, Quince Therapeutics, Inc. (QNCX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, QNCX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY). Compare QNCX vs RARE →
QNCX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| QNCXCurrent | $0 | - | - | - | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
QNCX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-142,000 | - | $-50,429,000 | - |
| 2024 | $0 | - | $0 | - | $-57,285,000 | - |
| 2023 | $0 | - | $0 | - | $-34,620,000 | - |
| 2022 | $0 | - | $0 | - | $-52,015,000 | - |
| 2021 | $0 | - | $0 | - | $-90,318,000 | - |
| 2020 | $0 | - | $0 | - | $-78,893,000 | - |
| 2019 | $0 | - | $0 | - | $-39,168,000 | - |
| 2018 | $0 | - | $-51,000 | - | $-12,119,000 | - |
| 2017 | $0 | - | $-45,000 | - | $-10,370,000 | - |
See QNCX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNCX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNCX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNCX — Frequently Asked Questions
Quick answers to the most common questions about buying QNCX stock.
Is QNCX's revenue growth accelerating or slowing?
QNCX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is QNCX's long-term revenue growth rate?
Quince Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is QNCX's revenue distributed by segment?
QNCX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.